Stifel on Cytokinetics (CYTK): 'We Think The Trial Likely Works, Positioning Afi As The Best/Only Drug Available For The Entire HCM Spectrum'

March 16, 2026 4:36 PM

Stifel analyst James Condulis reiterated a Buy rating and $98.00 price target on Cytokinetics (NASDAQ: CYTK)The analyst comments "We’re reiterating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

StreetInsider

Log in to your account:

Stifel on Cytokinetics (CYTK): 'We Think The Trial Likely Works, Positioning Afi As The Best/Only Drug Available For The Entire HCM Spectrum'

Categories